Pancreatic Cancer Research

ResearcherSecond Affiliated Hospital of Zhejiang UniversityActive in the last 2 years

Xueli Bai

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-6005-8384; OpenAlex author ID A5101698814. Sources: OpenAlex.

Their work

Papers
15 (first author 1, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
40
Papers, trials and grants by year

2015: 1 paper · 2016: 2 papers · 2017: none · 2018: 2 papers · 2019: 2 papers · 2020: 4 papers · 2021: none · 2022: none · 2023: none · 2024: none · 2025: 4 papers

Papers 15

  1. [18F]FAPI- 04 PET/CT for pathologic response assessment in pancreatic cancer patients with systemic treatment. Co-author DOI 10.1007/s00259-025-07271-6↗
  2. 5-Year survival rate over 20 % in pancreatic ductal adenocarcinoma: A retrospective study from a Chinese high-volume center. Co-author DOI 10.1016/j.canlet.2025.217658↗
  3. Neoadjuvant nab-paclitaxel plus gemcitabine followed by modified FOLFIRINOX for resectable pancreatic cancer: A randomized phase 3 trial. Co-author DOI 10.1016/j.ccell.2025.09.009↗
  4. Efficacy of Neoadjuvant Therapy and the Prognostic Significance of Serum Carcinoembryonic Antigen Level in Patients with Localized Pancreatic Adenocarcinoma wi… Co-author DOI 10.1097/sla.0000000000006719↗
  5. Calreticulin couples with immune checkpoints in pancreatic cancer. Co-author DOI 10.1002/ctm2.10↗
  6. Neoadjuvant chemotherapy for primary resectable pancreatic cancer: a systematic review and meta-analysis. Co-author DOI 10.1016/j.hpb.2020.01.001↗
  7. Eating self for not be eaten: Pancreatic cancer suppresses self-immunogenicity by autophagy-mediated MHC-I degradation. Co-author DOI 10.1038/s41392-020-0209-8↗
  8. [Developments and controversies in neoadjuvant therapy for resectable pancreatic cancer]. Co-author DOI 10.3760/cma.j.cn112139-20200422-00318↗
  9. B7-H5/CD28H is a co-stimulatory pathway and correlates with improved prognosis in pancreatic ductal adenocarcinoma. Co-author DOI 10.1111/cas.13914↗
  10. Association of Modified-FOLFIRINOX-Regimen-Based Neoadjuvant Therapy with Outcomes of Locally Advanced Pancreatic Cancer in Chinese Population. Last author DOI 10.1634/theoncologist.2018-0696↗
  11. Evaluation and proposal of novel resectability criteria for pancreatic cancer established by the Japan Pancreas Society. Co-author DOI 10.1016/j.surg.2017.12.029↗
  12. Liquid biopsy in pancreatic cancer: the beginning of a new era. First author DOI 10.18632/oncotarget.24809↗
  13. Pancreatic cancer adjuvant radiotherapy target volume design: based on the postoperative local recurrence spatial location. Co-author DOI 10.1186/s13014-016-0714-7↗
  14. [Modified FOLFIRINOX for advanced pancreatic cancer: a tertiary center experience from China]. Co-author DOI 10.3760/cma.j.issn.0529-5815.2016.04.006↗
  15. Characteristics of Tumor Infiltrating Lymphocyte and Circulating Lymphocyte Repertoires in Pancreatic Cancer by the Sequencing of T Cell Receptors. Co-author DOI 10.1038/srep13664↗

Closest collaborators

The 25 strongest of 40 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Tingbo Liang · 5 shared papers, 2020–2025 · strength 0.96
  2. Tingbo Liang · 9 shared papers, 2015–2020 · strength 0.84
  3. Guoliang Qiao · 3 shared papers, 2025 · strength 0.62
  4. Xiang Li · 3 shared papers, 2025 · strength 0.62
  5. Risheng Que · 4 shared papers, 2016–2025 · strength 0.52
  6. Yiwen Chen · 3 shared papers, 2019–2025 · strength 0.42
  7. Xiang Li · 3 shared papers, 2019–2025 · strength 0.42
  8. Tianan Jiang · 2 shared papers, 2025 · strength 0.39
  9. Qi Zhang · 2 shared papers, 2025 · strength 0.39
  10. Xing Huang · 2 shared papers, 2020 · strength 0.31
  11. Qi Zhang · 3 shared papers, 2015–2020 · strength 0.25
  12. Louisa Bolm · 1 shared paper, 2025 · strength 0.22
  13. Zhiyong Yang · 1 shared paper, 2025 · strength 0.22
  14. Motaz Qadan · 1 shared paper, 2025 · strength 0.22
  15. Keith D. Lillemoe · 1 shared paper, 2025 · strength 0.22
  16. Lili Lin · 1 shared paper, 2025 · strength 0.22
  17. Kang Sun · 1 shared paper, 2025 · strength 0.22
  18. Xinhui Su · 1 shared paper, 2025 · strength 0.22
  19. Yinan Shen · 2 shared papers, 2018–2019 · strength 0.19
  20. Tang Liang · 1 shared paper, 2020 · strength 0.19
  21. Qichun Wei · 3 shared papers, 2016–2019 · strength 0.18
  22. Ri‐Sheng Yu · 3 shared papers, 2016–2019 · strength 0.18
  23. Xiaozhen Zhang · 1 shared paper, 2020 · strength 0.16
  24. Tianyu Tang · 1 shared paper, 2020 · strength 0.15
  25. Tao Wei · 2 shared papers, 2015–2019 · strength 0.14

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.